A New Insulin Immunoassay Specific for the Rapid-Acting Insulin Analog, Insulin Aspart, Suitable for Bioavailability, Bioequivalence, and Pharmacokinetic Studies
Authors:
- Lennart AndersenLALennart Andersen
- Peer Nobert JørgensenPJPeer Nobert Jørgensen
- Lisbeth Bjerring JensenLJLisbeth Bjerring Jensen
- Declan WalshDWDeclan Walsh
- 1 November 2000
- journal article
- research article
- Published by Elsevier in Clinical Biochemistry
- Vol. 33 (8) , 627-633
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart.Diabetes Care, 1998
- Insulin analoguesThe Lancet, 1997
- UK Prospective Diabetes Study (UKPDS) XI: Biochemical Risk Factors in Type 2 Diabetic Patients at Diagnosis Compared with Age‐matched Normal SubjectsDiabetic Medicine, 1994
- Conversion of insulin units to SI unitsThe American Journal of Clinical Nutrition, 1993
- Enzyme immunoassay for intact human insulin in serum or plasmaClinical Chemistry, 1993
- Analytical Methods Validation: Bioavailability, Bioequivalence and Pharmacokinetic StudiesPharmaceutical Research, 1992
- In Vitro and In Vivo Potency of Insulin Analogues Designed for Clinical UseDiabetic Medicine, 1991
- Monomeric insulins obtained by protein engineering and their medical implicationsNature, 1988
- STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENTThe Lancet, 1986